REMARKS

Claims 27-36 are now pending, with claim 27 being the sole independent claim.

Claims 1-26 have been cancelled without prejudice to or disclaimer of the subject matter recited therein.

Claims 27-36 have been added. Support for the reference to "cyclin delta activity" in claim 27 is found at least in Example 10, the paragraph at page 30, lines 3-10 of the specification. Support for the sequence identities recited in claims 27-28 is found at least in the paragraph beginning on line 29 of page 6 and continuing onto page 7 of the specification. Support for the use of the term "recombinant" in claims 32 and 34-36 is found at least in the paragraph beginning on line 37 of page 10 and continuing onto page 11 of the specification. Support for claims 35-36 is found at least in Examples 7-8, pages 24-28 of the specification. No new matter has been added.

Applicants have amended the cross-reference to related applications section on page 1, lines 3-4, to indicate that the application is a divisional of U.S. Application No. 09/665,308, filed September 19, 2000, now pending, which is a continuation of International Application No. PCT/US99/06047, filed March 19, 1999, now expired, which claims the benefit of U.S. Provisional Application No. 60/078,948, filed March 23, 1998, now expired.

A substitute Sequence Listing is filed simultaneously herewith. As explained further in the Remarks for the 37 CFR 1.825(a) Amendment to Sequence Listing accompanying this substitute Sequence Listing, in SEQ ID NO:12, a 351 amino acid sequence (encoded by nucleotides 131-1186 of SEQ ID NO:11) replaces the originally-filed 339 amino acid sequence (encoded by nucleotides 167-1186 of SEQ ID NO:11).

A substitute Figure 2A-2B is submitted herewith. Figure 2 as originally filed contained the sequence of originally-filed SEQ ID NO:12, i.e., the 339 amino acid sequence mentioned above. The attached substitute Figure 2A-2B now contains the 351 amino acid sequence of SEQ ID NO:12 submitted in the substitute Sequence Listing filed simultaneously herewith. Additionally, in the sequence alignment of Figure 2 as originally filed, SEQ ID NOs:12 and 14 each also contained a period representing the stop codon of the corresponding nucleotide sequence, although these periods were not present in the Sequence Listing; in the sequence alignment of the substitute Figure 2A-2B, periods were not used for SEQ ID NOs:12 and 14, to be consistent with the currently amended Sequence Listing submitted herewith.

A substitute Figure 3A-3B is submitted herewith. Figure 3 as originally filed erroneously contained a partial amino acid sequence of 344 residues, instead of the entire 388 amino acid sequence of SEQ ID NO:18. The attached substitute Figure

3A-3B now contains, for SEQ ID NO:18, the entire 388 amino acid sequence of SEQ ID NO:18 as originally filed. Further basis for this amendment is found in the specification at page 3, lines 21-22, which describes Figure 3 as containing SEQ ID NO:18.

At page 3, lines 19-20, reference to Figure 2 has been amended to refer to Figures 2A and 2B.

At page 3, lines 21-22, reference to Figure 3 has been amended to refer to Figures 3A and 3B. Additionally, a spelling error has been corrected.

A currently amended Table 5, of Example 4, is submitted to correct the following errors in the original Table 5. First, the percent identity values in the original Table 5 were erroneously based on a comparison to the Arabidopsis delta-1 cyclin of GI No. 1076311, instead of to the highly similar Arabidopsis delta-1 cyclin of GI No. 3915635 (SEQ ID NO:30); the percent identity values of the amended Table 5 are based on GI No. 3915635 (SEQ ID NO:30), as referenced at page 20, lines 8-13 of the specification. Second, the percent identity value for SEQ ID NO:12 in the amended Table 5 was calculated using the amino acid sequence present in the currently amended Sequence Listing. Third, the percent identity values for some sequences of the original Table 5 were calculated using a "period" in the corresponding amino acid sequence to represent the stop codon; in the currently amended Table 5, all percent identity values were determined using the amino acid sequences present in the currently amended Sequence Listing, i.e., no periods were used to indicate the end of the protein.

A currently amended Table 7, of Example 5, is submitted to properly list the percent identity of the amino acid sequence of SEQ ID NO:18 when compared to the Nicotiana tabacum cyclin delta-2 protein (SEQ ID NO:31). The basis for this correction is page 22, lines 5-8 and lines 27-30 of the specification. In Table 7 as originally filed, the percent identities were erroneously calculated using a partial amino acid sequence of 344 residues for SEQ ID NO:18. A spelling error in the title of Table 7 is also corrected.

The specification has been amended at two locations to remove reference to the following URL: www.ncbi.nlm.nih.gov/BLAST/.

No new matter is believed to have been added.

Applicants further wish to note the following. The contig of SEQ ID NO:11 encodes a protein of 351 amino acids. Amino acids 11-351 (97% of the protein) are from the cDNA insert in clone sr1.pk0001.g5, and amino acids 1-10 are from the EST sequence of clone sah1c.pk003.i7. After the filing date of the priority application, Applicants sequenced the entire cDNA insert of sah1c.pk003.i7 and determined that this clone represents a different, but highly homologous, sequence to that of

sr1.pk0001.g5. Consequently, the joining of sequences from clones sr1.pk0001.g5 and sah1c.pk003.i7 created an artificial contig sequence.

With respect to U.S. Application No. 09/665,308, filed September 19, 2000, now pending, this divisional application is directed to the invention of Group I, drawn to an isolated polynucleotide, a chimeric gene, an expression vector, a method for transforming a cell, and a cell, classified in class 536, subclass 23.6, for example. Additionally, this divisional application is directed to SEQ ID NOs:17 and 18, wherein the amino acid sequence of SEQ ID NO:18 is encoded by nucleotides 275-1438 of SEQ ID NO:17, with nucleotides 1439-1441 of SEQ ID NO:17 encoding a stop codon.

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,

LORI Y. BEARDELL
Agent For Applicants
Registration No. 34,293
Telephone: 302-992-4926
Facsimile: 302-892-1026

Dated: 3/31/04

Enclosures: Substitute Figures 2A-2B and 3A-3B
1.825(a) Amendment to Sequence Listing
Substitute Sequence Listing; Paper Copy and CRF
Statement Under 1.825(a) and 1.825(b)